TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04398810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic single port cholecystectomy
Description: 1. Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~2. Residual gas aspiration~3. Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~4. Warming of the washing solution in the abdominal cavity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic single port cholecystectomy
Description: 1. Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~2. Residual gas aspiration~3. Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~4. Warming of the washing solution in the abdominal cavity
Study: NCT02297100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injections upper aspect of trigone of urinary bladder
Description: We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
Study: NCT02364297

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Early TIPS
Description: TIPS (first 5 days)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early TIPS
Description: TIPS (first 5 days)
Study: NCT02297100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injections on posterior bladder wall excluding the trigone
Description: We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
Study: NCT01025284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a 1-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a 1-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Administered subcutaneously
Study: NCT01587105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Case Management Service
Description: When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
Study: NCT02968108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects \>= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects \>= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at Week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects \>= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects \>= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at Week 8.
Study: NCT01563328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: 50 mg q24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: 50 mg q24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCV
Description: 800 mg q8h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: 750 mg q8h
Study: NCT02767778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REAL Pulsed ELF-MF stimulation
Description: Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Pulsed ELF-MF stimulation
Description: SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
Study: NCT03793647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical muscle devise
Description: evaluate two types of EMS stimulation of legs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical muscle devise
Description: evaluate two types of EMS stimulation of legs

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical muscle devise
Description: evaluate two types of EMS stimulation of legs
Study: NCT01534117

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelets
Description: 1 unit of platelets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDAVP
Description: Desmopressin 0.3mcg/kg IV x 1
Study: NCT03204617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)
Description: Vaccine DNA.HTI 0.5mL at weeks 0, 4 and 8 + Vaccine MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)
Description: At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
Study: NCT00798941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mouth care
Description: mouth spray, mouth swab, moisturizer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain intervention
Description: music and massage
Study: NCT02224612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medline Pediatric Face Masks
Description: Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medline Pediatric Face Masks
Description: Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medline Pediatric Face Masks
Description: Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KC Childs Mask
Description: KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KC Childs Mask
Description: KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KC Childs Mask
Description: KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
Study: NCT01520207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol (20%)
Description: 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
Study: NCT01684514

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Confocal laser endomicroscopy
Description: Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Description: Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image.
Study: NCT04330144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine as post exposure prophylaxis
Description: 1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Others(No intervention)
Description: No treatment. Close monitoring and quarantine.
Study: NCT01815658

Intervention type: DEVICE
Intervention: Carbon fiber intramedullary nail (PEEK-CF)
Description: Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
Study: NCT04245917

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional natural history study
Study: NCT00631982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro matuartion of oocytes
Description: in vitro maturation of (immature) oocytes
Study: NCT04552561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My MS Toolkit
Description: My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
Study: NCT04033978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: 10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial rehabilitation
Description: 10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
Study: NCT02991248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: robotic training
Description: robotic training by applying pelvis force perturbation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic training
Description: robotic training by applying pelvis force perturbation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord electrical stimulation
Description: Applying direct current electrical stimulation on spinal cord

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill
Description: conventional treadmill training only

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: conventional treadmill training only

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: treadmill
Description: conventional treadmill training only
Study: NCT01403558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy
Study: NCT00874913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measurement of ocular blood flow
Description: measurement of ocular blood flow with a laser Doppler flowmeter
Study: NCT00871624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
Study: NCT01156688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
Study: NCT01913834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forsteo
Description: Subcutaneous administration 20 micrograms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP046 PTH CriticalSorb
Description: Comparison of different doses of drug and nasal delivery devices

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP046 PTH CriticalSorb
Description: Comparison of different doses of drug and nasal delivery devices

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP046 PTH CriticalSorb
Description: Comparison of different doses of drug and nasal delivery devices

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP046 PTH CriticalSorb
Description: Comparison of different doses of drug and nasal delivery devices
Study: NCT04109781

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microscope assisted discectomy
Description: Microdiscectomy
Study: NCT01156688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
Study: NCT01999647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraneural Injection for Subgluteal Sciatic Nerve Block
Description: The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Injection for Subgluteal Sciatic Nerve Block
Description: The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Postoperative Analgesia
Description: Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
Study: NCT04419376

Intervention type: DEVICE
Intervention: driving pressure
Description: Mechanically ventilated patients (via ETT or trachestomy) were recorded for patients whose ventilation duration lasted at least 24 hours.We divided the patients into two groups by calculating the oxygenation index (OI): \[mean airway pressure(MAP) × fraction of inspired oxygen (FiO2) \]/ partial pressure of oxygen in arterial blood (PaO2) × 100) used in the classification of PALICC, including pARDS and non-pARDS.

Intervention type: DEVICE
Intervention: driving pressure
Description: Mechanically ventilated patients (via ETT or trachestomy) were recorded for patients whose ventilation duration lasted at least 24 hours.We divided the patients into two groups by calculating the oxygenation index (OI): \[mean airway pressure(MAP) × fraction of inspired oxygen (FiO2) \]/ partial pressure of oxygen in arterial blood (PaO2) × 100) used in the classification of PALICC, including pARDS and non-pARDS.
Study: NCT00599573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron 4mg BID for six weeks
Study: NCT03877861

Intervention type: DEVICE
Intervention: Readiband Sleep Tracking
Description: Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.

Intervention type: DEVICE
Intervention: Readiband Sleep Tracking
Description: Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
Study: NCT02205034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Intranasal administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Intranasal administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Intranasal administration
Study: NCT01606410

Intervention type: OTHER
Intervention: IPC
Description: repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
Study: NCT01999647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Controlled Postoperative Analgesia
Description: Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
Study: NCT00522548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric coated mycophenolate sodium
Description: Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
Study: NCT01507116

Intervention type: OTHER
Intervention: No treatment given
Description: Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.

Intervention type: OTHER
Intervention: No treatment given
Description: Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.

Intervention type: OTHER
Intervention: No treatment given
Description: Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
Study: NCT04750018

Intervention type: OTHER
Intervention: surgery
Description: Patients were divided into surgery and no disease.
Study: NCT00478270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bondronat]
Description: 6mg iv on days 1-3
Study: NCT00493012

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: 6 drops of a vitamin D containing oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 6 drops of a vitamin D containing oil
Study: NCT01105104

Intervention type: DEVICE
Group type: OTHER
Intervention: MedMinder System
Description: Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.

Intervention type: DEVICE
Group type: OTHER
Intervention: MedMinder System - deactivated
Description: Participants will receive a one-way reminder unit that will remotely transit information on medication adherence